Next Article in Journal
A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response
Next Article in Special Issue
Comparison of Tumor- and Bone Marrow-Derived Mesenchymal Stromal/Stem Cells from Patients with High-Grade Osteosarcoma
Previous Article in Journal
Can Plant Defence Mechanisms Provide New Approaches for the Sustainable Control of the Two-Spotted Spider Mite Tetranychus urticae?
Previous Article in Special Issue
Proteomic Differences in Feline Fibrosarcomas Grown Using Doxorubicin-Sensitive and -Resistant Cell Lines in the Chick Embryo Model
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(2), 615;

Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine

Division of Orthopedic Surgery, Department of Human Health, Federico II University of Naples, 80133 Naples, Italy
Division of Musculoskeletal Oncology Surgery, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy
Division of Pathology, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy
Division of Medical Oncology, National Cancer Institute, Pascale Foundation, 80131 Naples, Italy
Institute of Genetics and Biophysics “A. Buzzati Traverso”, National Research Council (CNR), 80131 Naples, Italy
Department of Biochemistry Biophysics and General Pathology, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 29 December 2017 / Revised: 13 February 2018 / Accepted: 16 February 2018 / Published: 21 February 2018
(This article belongs to the Special Issue Current Advances in Soft Tissue and Bone Sarcoma)
Full-Text   |   PDF [795 KB, uploaded 23 February 2018]   |  


Cancer treatment is rapidly evolving toward personalized medicine, which takes into account the individual molecular and genetic variability of tumors. Sophisticated new in vitro disease models, such as three-dimensional cell cultures, may provide a tool for genetic, epigenetic, biomedical, and pharmacological research, and help determine the most promising individual treatment. Sarcomas, malignant neoplasms originating from mesenchymal cells, may have a multitude of genomic aberrations that give rise to more than 70 different histopathological subtypes. Their low incidence and high level of histopathological heterogeneity have greatly limited progress in their treatment, and trials of clinical sarcoma are less frequent than trials of other carcinomas. The main advantage of 3D cultures from tumor cells or biopsy is that they provide patient-specific models of solid tumors, and they overcome some limitations of traditional 2D monolayer cultures by reflecting cell heterogeneity, native histologic architectures, and cell–extracellular matrix interactions. Recent advances promise that these models can help bridge the gap between preclinical and clinical research by providing a relevant in vitro model of human cancer useful for drug testing and studying metastatic and dormancy mechanisms. However, additional improvements of 3D models are expected in the future, specifically the inclusion of tumor vasculature and the immune system, to enhance their full ability to capture the biological features of native tumors in high-throughput screening. Here, we summarize recent advances and future perspectives of spheroid and organoid in vitro models of rare sarcomas that can be used to investigate individual molecular biology and predict clinical responses. We also highlight how spheroid and organoid culture models could facilitate the personalization of sarcoma treatment, provide specific clinical scenarios, and discuss the relative strengths and limitations of these models. View Full-Text
Keywords: spheroids; tumor microenvironment; sarcomas; precision medicine; personalized medicine spheroids; tumor microenvironment; sarcomas; precision medicine; personalized medicine

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Colella, G.; Fazioli, F.; Gallo, M.; De Chiara, A.; Apice, G.; Ruosi, C.; Cimmino, A.; de Nigris, F. Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine. Int. J. Mol. Sci. 2018, 19, 615.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top